Part 1: Understanding Tau Protein: Relevance in Health & Disease

Although a great deal of research has been dedicated to deciphering how tau contributes to neurodegenerative diseases like Alzheimer’s disease (AD), understanding its baseline function provides essential context to tau-related pathology.

Under normal conditions, tau is a highly regulated protein found throughout the central and peripheral nervous systems that is involved in neuronal health across every stage of development. Researchers are actively working to unravel tau’s role in normal biological processes and to understand how various tau isoforms and post-translational modifications impact neuronal function. While tau is often discussed as a static structural biomarker of neurodegeneration, it is a highly dynamic and biologically important protein that can provide rich insights into neuronal stability and survival.

In this three-part blog series, Aviva Systems Biology will perform a deep dive on tau proteins across health and disease. We’ll begin in this blog with an overview of tau’s normal role in neuronal biology, its relationship to microtubules, and the complexities of tau regulation in developmental stages and disease states. In the second part, we will then explore tau’s involvement in neurodegenerative processes and disease-associated changes. To conclude, we will outline some persistent questions in tau research and underscore how the advancement of research tools can help close the remaining gaps. 

Tau: Foundational to Neuronal Structure and Function

Tau is a microtubule-associated protein (MAP) primarily expressed in neurons, where it plays a critical role in maintaining the structure and function of the nervous system. Encoded by the MAPT gene, tau is found throughout both the central nervous system (CNS) and peripheral nervous system (PNS), particularly within axons, the long neuronal projections responsible for transmitting signals between cells. [1] Although tau is predominantly intracellular, researchers have also identified extracellular tau in cerebrospinal fluid and interstitial spaces, where it may contribute to cell-to-cell signaling and disease propagation. [2]

Under normal physiological conditions, tau is best known for its ability to bind and stabilize microtubules, the structural filaments that form part of the neuronal cytoskeleton. In addition to structural support, microtubules serve as essential “tracks” for intracellular transport, allowing proteins, organelles, and signaling molecules to move efficiently throughout the neuron. [3] Tau plays an essential role in normal neuronal health and function by facilitating microtubule assembly and stability, helping maintain axonal integrity and neuronal polarity. [4]

However, tau’s role extends beyond structural contributions alone. Emerging evidence suggests that tau participates in dynamic processes like neuronal signaling, synaptic plasticity, DNA protection, and responses to cellular stress.[5],[6] Tau localization can also shift depending on developmental stage, neuronal activity, and cellular environment, reflecting its highly dynamic nature. [7] Rather than functioning as a passive scaffold, tau appears to act as a responsive regulator of neuronal health and adaptability.

Not All Tau is Created Equal

Tau is not a single uniform protein; instead, it exists as multiple isoforms generated through tightly regulated alternative splicing of the MAPT gene. The MAPT gene contains 16 exons, and differential inclusion or exclusion of several exons yields a diverse range of mRNA transcripts and protein variants. These isoforms vary in both structure and function, with expression patterns that change throughout development and aging. [8]

In the adult human brain, alternative splicing produces six major tau isoforms ranging from 352 to 441 amino acids in length. These isoforms differ in the number of microtubule-binding repeat domains they contain, as well as the presence or absence of amino-terminal inserts. Broadly, tau isoforms are categorized as either three-repeat (3R) or four-repeat (4R) tau depending on whether they contain three or four microtubule-binding domains. The ratio of 3R to 4R tau is carefully regulated in healthy neurons, and disruptions in this ratio have been implicated in several neurodegenerative diseases. [3]

Tau isoform expression is also closely tied to neuronal maturation. [9] During fetal brain development, shorter tau isoforms that promote greater cytoskeletal flexibility are more highly expressed, supporting rapid axonal growth and remodeling. In contrast, adult neurons predominantly express isoforms associated with increased microtubule stabilization and mature neuronal architecture. [10] Although researchers recognize that tau splicing is critical for normal brain development, many questions remain regarding how individual isoforms contribute to neuronal resilience, plasticity, and vulnerability to disease.

Beyond alternative splicing, tau function is further regulated through post-translational modifications (PTMs), including phosphorylation, acetylation, ubiquitination, glycosylation, and truncation. [11] Among these, phosphorylation is the most extensively studied. In healthy neurons, tau phosphorylation is a normal and reversible process that helps regulate tau’s affinity for microtubules and its intracellular localization. Controlled phosphorylation allows neurons to dynamically remodel their cytoskeleton in response to developmental cues and cellular activity. [12]

Problems arise when tau becomes abnormally modified. Hyperphosphorylated tau has reduced affinity for microtubules and can detach from the cytoskeleton. In addition to inhibiting normal tau function, hyperphosphorylation increases the protein’s likelihood of self-aggregation into insoluble fibrils and neurofibrillary tangles, hallmark features of AD and other tauopathies. [13] Importantly, pathological tau is not defined solely by phosphorylation, but by complex combinations of PTMs, altered localization, and conformational changes that collectively disrupt normal cellular function.

Persistent Questions in the Field

Despite decades of intensive research, many aspects of tau biology remain unresolved. One major question centers on tau’s precise physiological functions outside of microtubule stabilization. Studies have suggested roles in synaptic transmission, RNA regulation, mitochondrial function, and even nuclear protection, but the extent and significance of these activities are still under investigation. [6],[14],[15],[16]

Another ongoing area of inquiry focuses on the mechanisms that drive tau pathology. Scientists continue to explore why tau transitions from a soluble, functional protein into toxic aggregated species and how different tau conformations influence disease progression. Researchers are additionally investigating whether distinct tau isoforms or PTM signatures contribute to specific neurodegenerative disorders. [17] Different tauopathies, including AD, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia (FTD), exhibit unique patterns of tau aggregation and isoform predominance. Understanding these disease-specific signatures may improve diagnostic precision and support the development of targeted therapeutics.

Tau localization itself is also a critical area of study. [18] While tau is primarily concentrated within axons under healthy conditions, disease-associated tau can mislocalize to the somatodendritic compartment, where it may interfere with synaptic signaling and neuronal communication. [19] Researchers are increasingly interested in understanding how changes in tau trafficking, secretion, and extracellular spread contribute to the development of neurodegenerative diseases. Advances in imaging, single-cell sequencing, proteomics, and stem cell modeling are rapidly expanding the field’s understanding of tau biology. At the same time, these technologies continue to reveal additional layers of complexity, emphasizing that tau is far more than a simple biomarker of neuronal damage.

Empowering Progress in Tau Research

As tau research advances, the need for sensitive, specific, and reproducible research tools has become increasingly important. Detecting subtle changes in tau isoform expression, phosphorylation status, localization, and aggregation requires highly validated antibodies and detection platforms capable of distinguishing between closely related tau species. [20]

Reliable tools are particularly critical as researchers work to characterize early pathological changes that occur long before overt neurodegeneration develops. [21] High-quality antibodies targeting total tau, phospho-tau epitopes, and disease-associated conformations can help investigators better understand tau dynamics across developmental stages, experimental models, and disease states.

At Aviva Systems Biology, supporting neuroscience researchers with rigorously validated antibodies and reagents is central to advancing discoveries in tau biology. As the field continues to uncover new complexities surrounding tau regulation and dysfunction, access to dependable detection tools will remain essential for driving meaningful progress.

Empower your tau research with the unmatched sensitivity and precision of Aviva’s total and phospho-tau ELISA kits.

And if you’re looking to learn more, download our eBook, ‘Neurodegenerative Disease Markers and Detection Methods'. 

References

[1] Avila, Jesús, et al. “Role of Tau Protein in Both Physiological and Pathological Conditions.” Physiological Reviews, vol. 84, no. 2, 2004, pp. 361–384. https://doi.org/10.1152/physrev.00024.2003.

[2] Avila, Jesús. “Intracellular and Extracellular Tau.” Frontiers in Neuroscience, vol. 4, 2010, article 49. https://doi.org/10.3389/fnins.2010.00049.

[3] Barbier, Pauline, et al. “Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects.” Frontiers in Aging Neuroscience, vol. 11, 2019, article 204. https://doi.org/10.3389/fnagi.2019.00204.

[4] Aranda-Abreu, Gonzalo E., et al. “The Role of Tau in Neuronal Function and Neurodegeneration.” Neurology International, vol. 17, no. 5, 2025, article 75. https://doi.org/10.3390/neurolint17050075.

[5] Mueller, Rachel L., et al. “Tau: A Signaling Hub Protein.” Frontiers in Molecular Neuroscience, vol. 14, 2021, article 647054. https://doi.org/10.3389/fnmol.2021.647054.

[6] Sultan, Abdelhamid, et al. “Nuclear Tau, a Key Player in Neuronal DNA Protection.” Journal of Biological Chemistry, vol. 286, no. 6, 2011, pp. 4566–4575. https://doi.org/10.1074/jbc.M110.199976.

[7] Tabeshmehr, Parisa, and Ehsan Eftekharpour. “Tau; One Protein, So Many Diseases.” Biology, vol. 12, no. 2, 2023, article 244. https://doi.org/10.3390/biology12020244.

[8] Corsi, Alessandra, et al. “Tau Isoforms: Gaining Insight into MAPT Alternative Splicing.” International Journal of Molecular Sciences, vol. 23, no. 23, 2022, article 15383. https://doi.org/10.3390/ijms232315383.

[9] Fiock, Kimberly L., et al. “Increased Tau Expression Correlates with Neuronal Maturation in the Developing Human Cerebral Cortex.” eNeuro, vol. 7, no. 3, 2020, article ENEURO.0058-20.2020. https://doi.org/10.1523/ENEURO.0058-20.2020.

[10] Bachmann, Stefan, et al. “Differential Effects of the Six Human TAU Isoforms: Somatic Retention of 2N-TAU and Increased Microtubule Number Induced by 4R-TAU.” Frontiers in Neuroscience, vol. 15, 2021, article 643115. https://doi.org/10.3389/fnins.2021.643115.

[11] Alquezar, Claudia, et al. “Tau Post-Translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation.” Frontiers in Neurology, vol. 11, 2021, article 595532. https://doi.org/10.3389/fneur.2020.595532.

[12] Hong, Xiaoyu, et al. “The Role and Pathogenesis of Tau Protein in Alzheimer’s Disease.” Biomolecules, vol. 15, no. 6, 2025, article 824. https://doi.org/10.3390/biom15060824.

[13] Gong, Cheng-Xin, and Khalid Iqbal. “Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease.” Current Medicinal Chemistry, vol. 15, no. 23, 2008, pp. 2321–2328. https://doi.org/10.2174/092986708785909111.

[14] Robbins, Megan, et al. “Synaptic Tau: A Pathological or Physiological Phenomenon?” Acta Neuropathologica Communications, vol. 9, no. 1, 2021, article 149. https://doi.org/10.1186/s40478-021-01246-y.

[15] Koren, Sarah A., et al. “Tau-Mediated Dysregulation of RNA: Evidence for a Common Molecular Mechanism of Toxicity in Frontotemporal Dementia and Other Tauopathies.” Neurobiology of Disease, vol. 141, 2020, article 104939. https://doi.org/10.1016/j.nbd.2020.104939.

[16] Castillo-Casaña, Yadira, et al. “Tau-Mitochondria Interactions in Neurodegeneration: Mechanisms and Therapeutic Potential.” Cellular and Molecular Neurobiology, vol. 46, no. 1, 2025, article 3. https://doi.org/10.1007/s10571-025-01634-1.

[17] Buchholz, Sarah, and Hans Zempel. “The Six Brain-Specific TAU Isoforms and Their Role in Alzheimer’s Disease and Related Neurodegenerative Dementia Syndromes.” Alzheimer’s & Dementia, vol. 20, no. 5, 2024, pp. 3606–3628. https://doi.org/10.1002/alz.13784.

[18] Kanaan, Nicholas M. “Tau Here, Tau There, Tau Almost Everywhere: Clarifying the Distribution of Tau in the Adult CNS.” Cytoskeleton, vol. 81, no. 1, 2024, pp. 107–115. https://doi.org/10.1002/cm.21820.

[19] Li, Chao, and Jürgen Götz. “Somatodendritic Accumulation of Tau in Alzheimer’s Disease Is Promoted by Fyn-Mediated Local Protein Translation.” The EMBO Journal, vol. 36, no. 21, 2017, pp. 3120–3138. https://doi.org/10.15252/embj.201797724.

[20] Mallick, Parag. “Single-Molecule Detection of Isoform-Specific Tau Phosphorylation.” Alzheimer’s & Dementia, vol. 18, suppl. S11, 2022, article e065032.

[21] O’Connor, Antoinette, et al. “Plasma Phospho-Tau181 in Presymptomatic and Symptomatic Familial Alzheimer’s Disease: A Longitudinal Cohort Study.” Molecular Psychiatry, vol. 26, no. 10, 2021, pp. 5967–5976. https://doi.org/10.1038/s41380-020-0838-x.